Eli Lilly and Company has announced an investment of $3.5 billion in a new manufacturing facility in Pennsylvania. The expansion is part of the company’s multi-year $50-billion investments in US capital expansion commitments made since 2020.   

The site will serve as Lilly’s newest injectable medicine and device manufacturing facility that will produce next-generation weight-loss therapies, including retatrutide, an investigational GIP, GLP-1 and glucagon triple hormone receptor agonist. Construction is expected to begin in 2026 with the site slated to be operational in 2031. 

This is the fourth of four new US manufacturing sites Lilly has announced since February 2025 as part of its commitment to bolster US medicine production. The new facility in Pennsylvania is a part of the company’s previously announced $50-billion capital investment commitment to expand US manufacturing capacity. The facility investments and focuses are broken down as follows:  

• Virginia: $5 billion for a new active pharmaceutical ingredient (API) and drug-product manufacturing facility, including for the company’s emerging bioconjugate platform and monoclonal antibody portfolio;   

• Texas: $6.5 billion for a new small-molecule API manufacturing facility;  

• Puerto Rico: $1.2 billion to expand an existing facility for oral solid medicines, including for manufacturing orforglipron, Lilly’s investigational oral, small-molecule GLP-1 receptor agonist for treating obesity and Type 2 diabetes.

Source: Eli Lilly and Company